Europe’s self-care industry leaders, policymakers and stakeholders are heading to Warsaw, Poland from 4-6 June this year for the Association of the European Self-Care Industry’s 61st Annual Meeting.
Over The Counter: What To Expect From The 61st AESGP Annual Meeting, With Jurate Švarcaite
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.

More from AESGP
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
“Despite there being a common regulatory framework for medicinal products in the European Union, there remains a diversity of approaches between EU member states with regards to how they regulate access to nonprescription medicines,” notes AESGP's Klavdija Kmetič, as the association updates its OTC ingredients directory.
When it comes to online consumer health product advertising, complying with regulations, ensuring that content is factually correct and being transparent are some of the key principles that companies should adhere to, recommends AESGP in a recently published position paper.
Real-world data and evidence, for example generated by digital consumer health technology like apps and wearables, could provide crucial support for Rx-to-OTC switch applications, argues Sanofi Consumer Healthcare’s Penny Glover at the Association of the European Self-Care Industry's 60th Annual Meeting in Brussels, Belgium. Recent research by Sanofi indicates that regulators are actually already using RWD and RWE in many cases when assessing switch applications, even if they do not call it that.
More from Business
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."